Lilly and Ascidian Sign $1.9B Deal to Bring RNA Gene Editing to Genetic Kidney Diseases
Eli Lilly teams with Ascidian to use RNA editing to treat rare kidney diseases without changing DNA.
/ 242 items
#XY Event-Driven Stocks↓
ADC Therapeutics Stock Falls as Safety Worries Overshadow Strong ZYNLONTA Trial Results
ADC Therapeutics fell by nearly half after ZYNLONTA showed better cancer control but higher rates of serious side effects and deaths.
FDA Fast-Tracks Verastem’s Breakthrough Oral Drug for KRAS G12D Lung Cancer
Verastem’s VS-7375 pill targets KRAS G12D lung cancer, a rare, hard-to-treat mutation with no approved drugs yet.
Mineralys Therapeutics Raises $650M+ in Capital Blitz to Clear Path for Lorundrostat Launch
Mineralys raised cash via $150M stock sale, $500M loan, and $200M royalty buyout to fund drug ahead of FDA decision; stock fell.
Briumvi’s New Subcutaneous Formulation Boosts TG Therapeutics Stock
TG Therapeutics stock rose after early trial results showed its under-skin MS drug worked well and may allow at-home dosing.
Wall Street Upgrades Rezolute After Strong Phase 3 Trial Results in Tumor Hyperinsulinism
Rezolute’s drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish.